Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufactures and supplies marketable molecules including specialty chemicals, vitamins & chemicals, and disinfectants. The company has a presence in Switzerland, UK, Europe, China, and other countries. Presenting below its Q1FY26 Earnings Results.
Q1 FY26 Earnings Results:
Revenue: ₹708 crore, up 35.11% year-on-year YoY from ₹524 crore
Total Expenses: ₹691 crore, up 15.55% YoY from ₹598 crore
Consolidated Net Profit PAT: ₹23 crore, a turnaround from a loss of -₹78 crore in the same quarter last year
Earnings Per Share EPS: ₹1.49, from -₹4.95 YoY
Operational & Strategic Update:
Revenue Growth: Revenue increased substantially by over 35%, driven by higher contract manufacturing volumes and broader product sales
Cost Control: Expenses grew by 15.55%, slower than revenue growth, reflecting improved operational efficiency and scale benefits
Profitability Turnaround: The company swung to a healthy net profit from a prior year loss, supported by better demand, product mix, and cost management
Business Focus: CRAMS and specialty chemical segments continued to show strong growth both domestically and internationally
Strategic Initiatives: Ongoing investments in capacity expansion, R&D, and global market outreach underpin the company’s growth trajectory
Corporate Developments in Q1 FY26:
Dishman Carbogen Amcis posted solid revenue growth and successfully returned to profitability, reflecting strategic business recovery and operational improvements.
Looking Ahead:
The company aims to sustain growth momentum by expanding contract manufacturing capabilities, diversifying product portfolio, and deepening global partnerships in FY26 and beyond.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.